These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31023256)

  • 1. BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
    Lu L; Huang H; Zhou J; Ma W; Mackay S; Wang Z
    BMC Cancer; 2019 Apr; 19(1):387. PubMed ID: 31023256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-step process of human breast carcinogenesis: a role for BRCA1, BECN1, CCND1, PTEN and UVRAG.
    Wu T; Li Y; Gong L; Lu JG; Du XL; Zhang WD; He XL; Wang JQ
    Mol Med Rep; 2012 Feb; 5(2):305-12. PubMed ID: 22011761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
    Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
    Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated T cell activation score is associated with improved survival of breast cancer.
    Lu L; Bai Y; Wang Z
    Breast Cancer Res Treat; 2017 Aug; 164(3):689-696. PubMed ID: 28488141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
    Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma.
    Lu L; Gaffney SG; Cannataro VL; Townsend J
    Oral Oncol; 2020 Feb; 101():104554. PubMed ID: 31887619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
    Chappuis PO; Donato E; Goffin JR; Wong N; Bégin LR; Kapusta LR; Brunet JS; Porter P; Foulkes WD
    Ann Oncol; 2005 May; 16(5):735-42. PubMed ID: 15802279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    Wen WX; Leong CO
    PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
    Ahlin C; Lundgren C; Embretsén-Varro E; Jirström K; Blomqvist C; Fjällskog M-
    Breast Cancer Res Treat; 2017 Aug; 164(3):667-678. PubMed ID: 28528450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
    Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
    Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of cyclin D1 genotype with breast cancer risk and survival.
    Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays.
    Bièche I; Olivi M; Noguès C; Vidaud M; Lidereau R
    Br J Cancer; 2002 Feb; 86(4):580-6. PubMed ID: 11870541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.
    Hao L; ElShamy WM
    Int J Cancer; 2007 Jul; 121(1):39-46. PubMed ID: 17278098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
    Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
    Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
    Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LINC00473 mediates cyclin D1 expression through a balance between activation and repression signals in breast cancer cells.
    Shi X; Wang X
    FEBS Lett; 2019 Apr; 593(7):751-759. PubMed ID: 30848493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined immune checkpoint blockade as a therapeutic strategy for
    Nolan E; Savas P; Policheni AN; Darcy PK; Vaillant F; Mintoff CP; Dushyanthen S; Mansour M; Pang JB; Fox SB; ; Perou CM; Visvader JE; Gray DHD; Loi S; Lindeman GJ
    Sci Transl Med; 2017 Jun; 9(393):. PubMed ID: 28592566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
    Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
    Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.